SCHEMBL4482464

SCHEMBL4482464

O=C(NNc1ncc(C(F)(F)F)cc1Cl)c1ccc(=O)n(Cc2c(Cl)cccc2Cl)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.60
MAPT P10636 5/20 0.60
MEN1 O00255 1/20 0.60
KMT2A Q03164 1/20 0.60
NPSR1 Q6W5P4 1/20 0.60
GAA P10253 10/20 0.52
POLB P06746 3/20 0.52
KDM4E B2RXH2 2/20 0.52
ALDH1A1 P00352 9/20 0.49
HTT P42858 6/20 0.46
NOD2 Q9HC29 1/20 0.46
AGTR1 P30556 4/20 0.45
LMNA P02545 4/20 0.43
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
TDP1 Q9NUW8 2/20 0.42
ALOX12 P18054 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4470067 0.76 GAA (0.59) SMN1; SMN2MAPTMEN1KMT2ANPSR1
SCHEMBL6471331 0.75 SMN1; SMN2 (0.59) SMN1; SMN2MAPTMEN1KMT2ANPSR1
SCHEMBL3523394 0.72 SMN1; SMN2 (0.52) SMN1; SMN2MAPTMEN1KMT2ANPSR1
SCHEMBL4542179 0.71 SMN1; SMN2 (0.59) SMN1; SMN2MAPTMEN1KMT2ANPSR1
SCHEMBL4537567 0.71 MAPT (0.59) SMN1; SMN2MAPTMEN1KMT2ANPSR1
SCHEMBL4542493 0.71 SMN1; SMN2 (0.59) SMN1; SMN2MAPTMEN1KMT2ANPSR1
SCHEMBL6115673 0.71 CYP2C9 (0.59) MAPTMEN1KMT2ANPSR1POLB
SCHEMBL7827542 0.69 GAA (0.77) SMN1; SMN2MAPTMEN1KMT2ANPSR1
SCHEMBL4481461 0.69 ALDH1A1 (0.56) SMN1; SMN2MAPTNPSR1POLBKDM4E
SCHEMBL4539932 0.68 SMN1; SMN2 (0.63) SMN1; SMN2MAPTMEN1KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US claimed
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
US-7067540-B2 Substituted pyridinones PHARMACIA CORPORATION (US) 2006-06-27 US disclosed
US-20050176775-A1 Substituted pyridinones PHARMACIA CORPORATION 2005-08-11 US disclosed
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058964-A1 Substituted pyridinones MAPK1, MAPK6, MAPK7 SMN1; SMN2 1433/4885MAPT 2803/4885MEN1 4261/4885
US-20050176775-A1 Substituted pyridinones MAPK1, MAPK6, MAP3K6 SMN1; SMN2 1419/4885MAPT 2543/4885MEN1 3919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.